on Biophytis (EPA:ALBPS)
Biophytis to Engage in Key Events in Q4 2025
Biophytis, a leading company in the field of longevity-focused therapies, will participate in four pivotal events in the fourth quarter of 2025. These events are set to mark strategic advancements for the company in the biotechnology sector.
The company will first attend the CF&B Midcap Events in Paris and Geneva. Here, Biophytis aims to interact with institutional investors, presenting development insights in areas such as sarcopenia and obesity.
In Vienna, at BIO-Europe 2025, Biophytis plans to meet potential partners and discuss strategic alliances that could bolster its clinical programs. This will be followed by the SCWD Annual Conference in Rome, where the company will present at a key scientific forum on muscle-wasting conditions, coinciding with the launch of a Phase 3 trial in sarcopenia.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Biophytis news